

PHILOGEN ANNOUNCES R&D PROGRAM UPDATE FOR DEKAVIL

Siena (Italy), 12 September 2021 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics today announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune diseases.

Dekavil will be investigated in novel clinical studies as a potential treatment in patients with certain Chronic Inflammatory conditions. Pfizer will continue to retain exclusive rights to further develop and commercialize Dekavil following the completion of the studies.

Designed as an “armed antibody”, Dekavil is composed of an antibody that selectively targets inflammatory disease sites in the body, coupled with the immunoregulatory cytokine interleukin-10 (IL-10). Unlike more traditional medicines that work by suppressing the immune system, Dekavil is believed to selectively modulate anti-inflammatory effects in the target area, sparing unwanted effects on other tissues and potentially restoring healthy immune function.

“We are committed to optimize the full potential of Dekavil under the license agreement with Pfizer. There is a substantial biomedical rationale to use the anti-inflammatory properties of targeted IL-10 for the treatment of Rheumatoid Arthritis. If the clinical trials give a positive signal, it is conceivable that the product could be tested in additional indications.” commented Prof. Dario Neri, co-founder and Chief Executive Officer of Philogen.

“The antibody-based targeted delivery of anti-inflammatory payloads is a highly attractive strategy for the potential treatment of chronic inflammatory conditions. The new studies will likely help to increase our knowledge in the field of targeted cytokines.” commented Jeremy Gale, Vice President, Inflammation & Immunology, Pfizer.

About Philogen

Philogen is a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. It is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and philochem.com

Forward-Looking Statements

The forward-looking statements contained in this press release may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forwardlooking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; anticipated enrollment in and progression of Philogen’s clinical trials; the availability of data from clinical trials and preclinical studies; anticipated regulatory filings; the therapeutic potential of Philogen’s product candidates; Philogen’s ability to achieve planned milestones. Philogen may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue

reliance on these forwardlooking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Philogen's and its partners' abilities to meet other anticipated deadlines and milestones, also due to the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Philogen's product candidates by Philogen or its partners; the risk that Philogen may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Philogen's product candidates; risks related to Philogen's ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; other factors which could cause our actual result to differ from those contained in the forward-looking statements, as also described in greater detail in the Risk Factors section in the prospectus drafted by Philogen and approved by Consob on February 17, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Philogen expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. The information and contents of this press release do not: (i) constitute an order or an offer to purchase or to sell financial products or financial services; (ii) relate to special investment goals or to the financial situation or particular requirements of specific users. All information presented, reports published and opinions expressed are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the press release is not to be understood as an invitation or recommendation to buy or sell securities of Philogen, or as an advertisement for securities of Philogen. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives. The mere use of the website does not give rise to any contractual relationship of any kind between the user and Philogen. Philogen expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. Philogen provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision. The material contained on the website does not relieve the user from having to make his own decisions. This press release may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of Philogen. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. Philogen accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties, and gives no assurances of any kind in this regard. Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties, and shall not be liable for the content or web pages of third parties which are linked to the Philogen website or which display the Philogen website in frames.

Philogen contacts

Dr. Christian Lizak (Business Development), Dr. Emanuele Puca (Investor Relations) +41 (0) 43 544 88 00
christian.lizak@philogen.com, emanuele.puca@philogen.com

Consilium Strategic Communications contacts

Mary-Jane Elliott, Melissa Gardiner, Davide Salvi Philogen@consilium-comms.com